Literature DB >> 21953322

High-mobility group box 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma.

Wei Jiang1, Zhiming Wang, Xinying Li, Xuegong Fan, Yankun Duan.   

Abstract

High-mobility group box 1(HMGB1) has been associated with many human cancers, but the role of HMGB1 in hepatocellular carcinoma (HCC) remains unclear. The aim of this study is to investigate the expression of HMGB1 in human HCC with regard to its clinical significance. Twelve cases of normal liver tissues, 34 cases of HCC and the corresponding liver tissue just around the tumor (LAT) were collected. Then, all the samples were subjected to clinicopathologic examination, reverse transcription-polymerase chain reaction (RT-PCR), Western-blot (WB) and immunohistochemical analysis for the expression of HMGB1. The relationships between HMGB1 mRNA expression and clinicopathologic parameters were analyzed. RT-PCR demonstrated that the expression of relative HMGB1 mRNA (HMGB1/GAPDH) was 0.854 ± 0.172; the highest in the tissue of HCC, significantly up-regulated compared with that of 0.527 ± 0.155 in LAT and of 0.405 ± 0.087 in normal liver tissues (P < 0.001). HMGB1 mRNA overexpression was significantly associated with Edmondson stage, TNM stage, vascular invasion and capsule invasion. Western-blot showed the expression of HMGB1 protein in HCC also as the highest among all the groups. Furthermore this overexpression revealed by immunostaining was predominantly localized in the nuclei of HCC; whereas, none of the stains were seen in normal liver cells and only a trace of it was detected in the cytoplasm of LAT cells. Our results suggested the overexpression of HMGB1 might be an important pathogenetic factor in HCC. The mechanisms of HMGB1 in HCC genesis, development and its possible diagnostic and prognostic roles need to be further explored.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21953322     DOI: 10.1007/s12253-011-9442-3

Source DB:  PubMed          Journal:  Pathol Oncol Res        ISSN: 1219-4956            Impact factor:   3.201


  23 in total

Review 1.  HMG1 and 2, and related 'architectural' DNA-binding proteins.

Authors:  J O Thomas; A A Travers
Journal:  Trends Biochem Sci       Date:  2001-03       Impact factor: 13.807

Review 2.  New EMBO members' review: the double life of HMGB1 chromatin protein: architectural factor and extracellular signal.

Authors:  S Müller; P Scaffidi; B Degryse; T Bonaldi; L Ronfani; A Agresti; M Beltrame; M E Bianchi
Journal:  EMBO J       Date:  2001-08-15       Impact factor: 11.598

3.  Monocytic cells hyperacetylate chromatin protein HMGB1 to redirect it towards secretion.

Authors:  Tiziana Bonaldi; Fabio Talamo; Paola Scaffidi; Denise Ferrera; Annalisa Porto; Angela Bachi; Anna Rubartelli; Alessandra Agresti; Marco E Bianchi
Journal:  EMBO J       Date:  2003-10-15       Impact factor: 11.598

4.  Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies.

Authors:  H A EDMONDSON; P E STEINER
Journal:  Cancer       Date:  1954-05       Impact factor: 6.860

5.  Angiogenetic signaling through hypoxia: HMGB1: an angiogenetic switch molecule.

Authors:  Claudia Schlueter; Holger Weber; Britta Meyer; Piere Rogalla; Kerstin Röser; Sven Hauke; Jörn Bullerdiek
Journal:  Am J Pathol       Date:  2005-04       Impact factor: 4.307

Review 6.  High-mobility group box 1 protein (HMGB1): nuclear weapon in the immune arsenal.

Authors:  Michael T Lotze; Kevin J Tracey
Journal:  Nat Rev Immunol       Date:  2005-04       Impact factor: 53.106

7.  Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer.

Authors:  Hiroki Kuniyasu; Naohide Oue; Atsuko Wakikawa; Hideo Shigeishi; Norimasa Matsutani; Kazuya Kuraoka; Reiko Ito; Hiroshi Yokozaki; Wataru Yasui
Journal:  J Pathol       Date:  2002-02       Impact factor: 7.996

8.  Expression of high mobility group box chromosomal protein-1 (HMGB-1) in gastric cancer.

Authors:  Hidenori Akaike; Koji Kono; Hidemitsu Sugai; Akihiro Takahashi; Kousaku Mimura; Yoshihiko Kawaguchi; Hideki Fujii
Journal:  Anticancer Res       Date:  2007 Jan-Feb       Impact factor: 2.480

9.  Serum high mobility group box chromosomal protein 1 is associated with clinicopathologic features in patients with hepatocellular carcinoma.

Authors:  B-Q Cheng; C-Q Jia; C-T Liu; X-F Lu; N Zhong; Z-L Zhang; W Fan; Y-Q Li
Journal:  Dig Liver Dis       Date:  2008-02-21       Impact factor: 4.088

Review 10.  Specific molecular markers in hepatocellular carcinoma.

Authors:  Deng-Fu Yao; Zhi-Zhen Dong; Min Yao
Journal:  Hepatobiliary Pancreat Dis Int       Date:  2007-06
View more
  17 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  HMGB1 overexpression correlates with poor prognosis in early-stage squamous cervical cancer.

Authors:  Yirong Xu; Zhenwen Chen; Guangheng Zhang; Yanfeng Xi; Ruifang Sun; Fei Chai; Xiaogang Wang; Jianhong Guo; Lin Tian
Journal:  Tumour Biol       Date:  2015-06-18

Review 3.  HMGB1 in health and disease.

Authors:  Rui Kang; Ruochan Chen; Qiuhong Zhang; Wen Hou; Sha Wu; Lizhi Cao; Jin Huang; Yan Yu; Xue-Gong Fan; Zhengwen Yan; Xiaofang Sun; Haichao Wang; Qingde Wang; Allan Tsung; Timothy R Billiar; Herbert J Zeh; Michael T Lotze; Daolin Tang
Journal:  Mol Aspects Med       Date:  2014-07-08

4.  HMGB1 silence could promote MCF-7 cell apoptosis and inhibit invasion and metastasis.

Authors:  Ping Ni; Yongjian Zhang; Yueqin Liu; Xin Lin; Xiaolian Su; Hongxiang Lu; Huiling Shen; Wenlin Xu; Huaxi Xu; Zhaoliang Su
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

Review 5.  Emerging role of high-mobility group box 1 (HMGB1) in liver diseases.

Authors:  Ruochan Chen; Wen Hou; Qiuhong Zhang; Rui Kang; Xue-Gong Fan; Daolin Tang
Journal:  Mol Med       Date:  2013-11-08       Impact factor: 6.354

6.  High expression of high mobility group box 1 (hmgb1) predicts poor prognosis for hepatocellular carcinoma after curative hepatectomy.

Authors:  Furong Liu; Yaojun Zhang; Zhenwei Peng; Hengjun Gao; Li Xu; Minshan Chen
Journal:  J Transl Med       Date:  2012-07-02       Impact factor: 5.531

Review 7.  The association of HMGB1 expression with clinicopathological significance and prognosis in hepatocellular carcinoma: a meta-analysis and literature review.

Authors:  Lu Zhang; Jianjun Han; Huiyong Wu; Xiaohong Liang; Jianxin Zhang; Jian Li; Li Xie; Yinfa Xie; Xiugui Sheng; Jinming Yu
Journal:  PLoS One       Date:  2014-10-30       Impact factor: 3.240

8.  Association of Upregulated HMGB1 and c-IAP2 Proteins With Hepatocellular Carcinoma Development and Progression.

Authors:  Man Ru Bi; Li Ying Zhu; Bing Zhu Yan; Li Yan Chen; Fu Xiang Wang; Ying Ji Ma; Bao Shan Yang
Journal:  Hepat Mon       Date:  2014-12-15       Impact factor: 0.660

9.  Down-regulation of HMGB1 expression by shRNA constructs inhibits the bioactivity of urothelial carcinoma cell lines via the NF-κB pathway.

Authors:  Zhichao Huang; Zhaohui Zhong; Lei Zhang; Xinjun Wang; Ran Xu; Liang Zhu; Zijian Wang; Shanbiao Hu; Xiaokun Zhao
Journal:  Sci Rep       Date:  2015-08-04       Impact factor: 4.379

10.  The role of HMGB1-RAGE axis in migration and invasion of hepatocellular carcinoma cell lines.

Authors:  Ruo-Chan Chen; Pan-Pan Yi; Rong-Rong Zhou; Mei-Fang Xiao; Ze-Bing Huang; Dao-Lin Tang; Yan Huang; Xue-Gong Fan
Journal:  Mol Cell Biochem       Date:  2014-02-09       Impact factor: 3.396

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.